Article
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Clinical and translational science - 1 Mar 2021
Hohmann Nicolas, Bozorgmehr Farastuk, Christopoulos Petros, Mikus Gerd, Blank Antje, Burhenne Jürgen, Thomas Michael, Haefeli Walter E
Abstract excerpt
The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK-positive non-small cell lung cancer (NSCLC). When evaluating crizotinib pharmacokinetics (PKs) in patients taking the standard flat oral dose of 250 mg b.i.d., interindividual PK variability is substantial and patient survival is lower in the quartile with the lowest steady-state trough plasma...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.